Cointime

NeuralStem

company

About

Neuralstem, a biotherapeutics company, aims to apply stem cell research and technology to treat diseases of the central nervous system.

  • 1 - 10

Highlights

Total Funding Amount
$28M
Funding Rounds
2
Investors
2

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
$8M
Industries
Biotechnology,Health Care,Neuroscience,Therapeutics
Founded date
Jan 1, 1996
Number Of Employee
1 - 10
Operating Status
Active

Neuralstem, Inc. is a publicly traded biotherapeutics company.

The company aims to apply "stem cell research and its patented human neural stem cell technology to treat diseases of the central nervous system including Ischemic Paraplegia, Traumatic Spinal Cord Injury, ALS and Parkinson’s Disease." Neuralstem's research has allowed them to produce mature, commercial quantities of neural stem cells that can be transplanted into humans as treatments for currently incurable diseases.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$28M
NeuralStem has raised a total of $28M in funding over 2 rounds. Their latest funding was raised on Dec 12, 2016 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 12, 2016 Post-IPO Equity $20M 1 Tianjin Pharmaceutical Group International Holdings — Detail
Mar 25, 2013 Post-IPO Debt $8M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
1
2
NeuralStem is funded by 2 investors. Tianjin Pharmaceutical Group International Holdings and Hercules Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Tianjin Pharmaceutical Group International Holdings Yes Post-IPO Equity
Hercules Capital — Post-IPO Debt
Cointime
เนื้อหา
บริษัท